In the past quarter, Aclaris Therapeutics (NASDAQ:ACRS) has received ratings from four analysts. Among them, three analysts are optimistic about the company’s prospects, while one analyst holds a slightly bullish view. None of the analysts are indifferent, somewhat bearish, or bearish towards the company. The average price target given by these analysts is $36.0, which represents a significant increase of 125.0% from Aclaris Therapeutics’ current price of $7.39.
Based on the ratings of four Wall Street analysts, Aclaris Therapeutics’ analyst rating consensus is a Strong Buy, according to TipRanks. The company has an average rating score of 3.00, derived from seven buy ratings, no hold ratings, and no sell ratings.
Furthermore, analysts have forecasted a potential upside of 295.6% for Aclaris Therapeutics, with a consensus price target of $32.00, compared to its current price of $8.09.
Aclaris Therapeutics, Inc.
ACRS
Neutral
Updated on: 21/09/2023
Weak 
Debt to equity ratio: Neutral 
ACRS Stock Performance on September 19, 2023: Mixed Performance with Potential for Future Profitability in the Pharmaceutical Industry
ACRS Stock Performance on September 19, 2023:
Previous Close: $7.43
Today’s Open: $7.36
Day’s Range: $7.34 – $7.51
Volume: 21,284 shares traded
Market Cap: $534.5 million
Earnings Growth: +16.79% over the past year, -34.22% this year, +38.60% expected over the next five years
Revenue Growth: +340.05% over the past year
P/E Ratio: NM (not meaningful)
Price/Sales Ratio: 34.52
Price/Book Ratio: 2.55
Sector and Industry: Health Technology, Pharmaceuticals: Major
Corporate Headquarters: Wayne, Pennsylvania
Overall, ACRS stock had a mixed performance on September 19, 2023. The stock opened slightly lower than the previous close and experienced some volatility throughout the day. The lower trading volume suggests less investor interest, but the positive earnings and revenue growth over the past year indicate potential for future profitability. Investors should continue to monitor ACRS stock and consider its growth prospects in the pharmaceutical industry.
ACRS Stock Analysis: Strong Performance and Potential Upside for Aclaris Therapeutics Inc
On September 19, 2023, Aclaris Therapeutics Inc (ACRS) showcased a strong performance in the stock market. With a median target price of $29.50, analysts are predicting a potential increase of 298.92% from the last recorded price of $7.40. This positive outlook has been consistent since September, when the consensus among 8 investment analysts was to buy ACRS stock.
The data, sourced from CNN Money, reveals that Aclaris Therapeutics Inc has received price forecasts from 8 analysts. The median target price of $29.50 indicates a significant upside potential. The high estimate of $43.00 and the low estimate of $20.00 further highlight the range of possibilities for ACRS stock.
Investors can find reassurance in the fact that the consensus rating to buy Aclaris Therapeutics Inc stock has remained steady since September. This suggests that analysts have confidence in the company’s future performance and growth prospects.
In terms of financials, Aclaris Therapeutics Inc reported earnings per share of -$0.47 for the current quarter. While this figure indicates a loss, it is important to note that earnings per share can fluctuate and may not be a comprehensive reflection of a company’s overall financial health. Additionally, Aclaris Therapeutics Inc reported sales of $2.0 million for the same period.
Looking ahead, investors can anticipate the reporting of Aclaris Therapeutics Inc’s financial results on November 7. This will provide a more comprehensive understanding of the company’s performance and may have an impact on the stock’s future trajectory.
Overall, ACRS stock exhibits promising potential based on the median target price and the consensus rating among investment analysts. However, it is important for investors to conduct their own research and consider various factors before making any investment decisions.
Discussion about this post